The goal of the partnership between Life Image and Graticule is to improve clinical trial results and accelerate drug development, while reducing costs, say company executives.
With global health care ‘at a tipping point,’ NSF International expands its services across the product lifecycle with the acquisition of a US-headquartered CRO, says VP.
The FDA has published the second in a series of guidance documents that aim to accelerate research and the use of patient input to inform clinical development programs, says Iqvia head.
Charles River Laboratories recently announced that Alzheimer’s Research UK selected the company to join the Dementia Consortium to help researchers progress projects to in vivo proof of concept.
The clinical trials software company has raised $7.1m to connect its network of more than 5,000 clinical trial sites with sponsors and CROs via the ‘Florence eHub.’
N4 Pharma creates DNA and RNA transfection technology using silica nanoparticles with an irregular surface, which traps and protects nucleic acid during its journey to cells.
GSK taps Lyell’s technology to delay ‘exhaustion’ of T cells and will explore creating a new platform to develop cell and gene therapies for rare cancers.
TriNetX is a new technology partner working on the FDA’s Sentinel System, led by HPHCI, which has signed a contract worth up to $220m to develop a new Sentinel Innovation Center.
A fellowship program run by Worldwide Clinical Trials aims to equip scientists with the skills to meet industry demands for ‘informed, differentiated’ services.
Insilico Medicine will use its next-generation AI platform to accelerate CRFH’s drug discovery and development efforts – a deal that exemplifies maturation in the market as researchers explore new ways to conduct R&D.
Beacon of Hope CRO is working with sponsors and other service providers to design Right to Try treatment programs, which the company’s founder says have ‘unmatched’ flexibility, an ability to treat screen fails and create ‘interim clinical milestones,’...
Three organizations have merged to form Apex Innovative Sciences, an independent clinical trial site operator focused on Phase I-IV studies for central nervous system indications and other therapeutic areas, including neurology, psychiatry, addiction,...
Through a recently announced partnership with TrialSpark, 23andMe has entered the clinical trials market – an area in which the direct-to-consumer genetic testing company feels it has the potential to grow.
Parexel increases its real world data network by more than 330m patients across 60 health care and consumer sources though a partnership with HealthVerity – which earlier this year raised $25m to advance its technology.
